SCHEMBL7044266

SCHEMBL7044266

COc1nn(-c2ccc(NC(=O)c3ccc(Cl)c(Cl)c3)cc2)c(=O)o1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPL P06858 1/20 0.70
LIPC P11150 1/20 0.70
LIPE Q05469 1/20 0.70
BCAT2 O15382 1/20 0.51
FAAH O00519 3/20 0.51
MGLL Q99685 3/20 0.51
ABHD16A O95870 1/20 0.50
KDM4E B2RXH2 3/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
NPC1 O15118 1/20 0.49
MAPT P10636 1/20 0.49
PKM P14618 1/20 0.49
RAB9A P51151 1/20 0.49
KDR P35968 1/20 0.46
KCNQ3 O43525 1/20 0.46
KCNQ2 O43526 1/20 0.46
KCNE1 P15382 1/20 0.46
KCNQ1 P51787 1/20 0.46
MAOA P21397 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6603718 0.84 LPL (0.69) LPLLIPCLIPEFAAHMGLL
SCHEMBL7047919 0.83 LPL (1.00) LPLLIPCLIPEFAAHMGLL
SCHEMBL6604642 0.81 LPL (0.62) LPLLIPCLIPEFAAHMGLL
SCHEMBL6602780 0.81 LPL (0.74) LPLLIPCLIPEFAAHMGLL
SCHEMBL6601943 0.80 LPL (0.72) LPLLIPCLIPEFAAHMGLL
SCHEMBL6604889 0.80 LPL (0.72) LPLLIPCLIPEFAAHMGLL
SCHEMBL6603513 0.78 LPL (0.64) LPLLIPCLIPEFAAHMGLL
SCHEMBL7047839 0.77 MGLL (0.58) LPLLIPCLIPEFAAHMGLL
SCHEMBL7044283 0.77 LPL (0.67) LPLLIPCLIPEFAAHMGLL
SCHEMBL6600553 0.75 LPL (0.62) LPLLIPCLIPEFAAHMGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030236288-A1 Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase AVENTIS PHARMA DEUTSCHLAND GMBH 2003-12-25 US disclosed
US-6369088-B2 ANTIDIABETIC AGENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-09 US disclosed
US-20010031772-A1 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031772-A1 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals CNR1, PTGER1, CNR2 LPL 1845/4885LIPC 554/4885LIPE 1909/4885
US-20030236288-A1 Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase PNLIP, CEL, LIPE LPL 4/4885LIPC 7/4885LIPE 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.